Telix ADRs rise after FDA approves Pixclara brain imaging
Telix Pharmaceuticals Limited ADRs gained after the FDA approved its new drug application for Pixclara, used in brain cancer imaging; ADRs rose 7.9% to $12.18 in premarket.
American depositary receipts of Telix Pharmaceuticals Limited climbed after the Food and Drug Administration approved the company’s new drug application for Pixclara, a drug used in brain cancer imaging. The ADRs were up 7.9% to $12.18 in premarket trading on Monday. As of Friday’s market close, they had gained 7.9% to $12.18.